Welcome to our dedicated page for RWLK news (Ticker: RWLK), a resource for investors and traders seeking the latest updates and insights on RWLK stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect RWLK's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of RWLK's position in the market.
ReWalk Robotics (NASDAQ: RWLK) has appointed Randel Richner to its Board of Directors, effective November 1, 2020. Richner brings over 30 years of expertise in public health policy, particularly in medical devices and reimbursement strategy. Her previous roles include serving on the Advisory Board for CMS and leading global reimbursement at Boston Scientific. Chairman Jeff Dykan highlighted her ability to strategically influence government policies relevant to ReWalk's exoskeleton technology. Richner aims to enhance access to groundbreaking technologies for individuals with disabilities.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced its participation at the H.C. WAINWRIGHT virtual conference taking place on September 15, 2020, at 11:00 EST. Presenting will be CEO Larry Jasinski, CFO Ori Gon, and VP of Marketing Andy Dolan. A live and archived webcast of the presentation will be accessible on the company’s investor website, www.rewalk.com. ReWalk specializes in developing wearable robotic exoskeletons aimed at enhancing the quality of life for individuals with lower limb disabilities resulting from spinal cord injuries or strokes.
ReWalk Robotics Ltd. (RWLK) reported a significant revenue increase of $1.7 million in Q2 2020, up from $0.9 million in Q2 2019, primarily due to higher sales of ReWalk Personal 6.0 units in Germany and the U.S. The company achieved a record gross margin of 61.3%, improving from 49.6% year-over-year, supported by higher unit sales and prices. Operating expenses decreased to $3.6 million from $4.7 million, while net loss reduced to $2.9 million. ReWalk raised $10.6 million from warrants exercise and offerings, enhancing liquidity with $14.1 million in cash.
On July 15, 2020, ReWalk Robotics (Nasdaq: RWLK) announced that the Centers for Medicare and Medicaid Services (CMS) issued HCPCS Level II Code K1007, the first coding for exoskeletons, effective October 1, 2020. This breakthrough aims to enhance access to ReWalk's robotic devices for individuals with spinal cord injuries. The company plans to collaborate with Medicare and private insurers for payment rates and coverage policies, ultimately enabling eligible individuals to obtain ReWalk devices for home use.
ReWalk Robotics Ltd. (Nasdaq: RWLK) has completed a registered direct offering of approximately 4,938,278 ordinary shares at $1.8225 each, raising nearly $9.0 million. The company plans to use the proceeds for sales and marketing of its ReStore device, R&D for its exo-suit technology, and general corporate purposes. Additionally, ReWalk issued warrants to purchase 2,469,139 ordinary shares at an exercise price of $1.76, valid for five and a half years. H.C. Wainwright & Co. served as the exclusive placement agent for this offering.
ReWalk Robotics Ltd. (Nasdaq: RWLK) announced a registered direct offering to issue approximately 4,938,278 ordinary shares at $1.8225 per share, generating gross proceeds of around $9.0 million. The offering is expected to close by July 6, 2020. Investors will also receive unregistered warrants for an additional 2,469,139 shares at an exercise price of $1.76. The proceeds will fund marketing for the ReStore device, R&D for new products, and general corporate purposes. H.C. Wainwright & Co. is acting as the exclusive placement agent.
On June 22, 2020, ReWalk Robotics (RWLK) announced the publication of results from a clinical study on the ReStore Exo-Suit, designed for stroke rehabilitation. Conducted across five major U.S. rehabilitation institutions, the study showcased the device's safety and its impact on functional walking. Notably, 64% of participants improved their unassisted walking speed. The results affirm the ReStore Exo-Suit as a pioneering solution in rehabilitation technology, addressing the needs of the approximately 800,000 Americans who suffer from strokes annually.
ReWalk Robotics (RWLK) has finalized agreements to distribute new product lines in the U.S., enhancing its portfolio in stroke rehabilitation and spinal cord injury care. The company will exclusively distribute MediTouch Tutor movement biofeedback systems and MYOLYN MyoCycle Functional Electrical Stimulation cycles for rehabilitation clinics and VA hospitals. These additions aim to increase sales opportunities and access to new customers, particularly in the growing telehealth market. Commercial activities are expected to begin in July 2020.
ReWalk Robotics Ltd. (RWLK) will release its Q1 2020 financial results on May 28, 2020, before the U.S. markets open. CEO Larry Jasinski and CFO Ori Gon will host a conference call at 8:30 A.M. EST to discuss the results. Shareholders can participate using the provided toll-free numbers or access the webcast through the company's investor relations section. ReWalk develops wearable robotic exoskeletons aimed at improving the quality of life for individuals with lower limb disabilities due to spinal cord injuries or strokes.